Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Acclarent

M&A STATUS
201-300 EMPLOYEES
M&A LATEST DEAL TYPE
$785M LATEST DEAL AMOUNT
Description

Designer and developer of technologies that address conditions affecting the ear, nose, and throat. The company primarily focuses on commercializing Balloon Sinuplasty devices, which are minimally-invasive tools that aid physicians in treating patients suffering from chronic sinusitis, as well as in sinus surgery. Its devices are specifically designed to navigate the sinus anatomy and open blocked sinus ostia and passageways to allow for sinus drainage.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Other Industries
Medical Supplies
Acquirer
Primary Office
  • 33 Technology Drive
  • Irvine, CA 92618
  • United States

+1 (877) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Acclarent’s full profile, request a free trial.

Acclarent Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 20-Jan-2010 $785M 00000 00000 Completed Generating Revenue/Not Profitable
5. IPO 06-Jun-2008 000.00 Cancelled Generating Revenue/Not Profitable
4. Later Stage VC (Series D) 31-Mar-2008 0000 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 23-Apr-2007 0000 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 27-Dec-2005 $28M $42.6M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-2003 $14.5M $14.5M 000.00 Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Acclarent Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 0,000,000 00.00 00.00 00.00 00 00.00 0.000
Series C 00,000,000 00.00 00.00 00.00 00 00.00 00.00
Series B 13,357,773 $0.17 $2.1 $2.1 1x $2.1 22.7%
Series A 14,071,484 $0.08 $1.04 $1.04 1x $1.04 23.78%
To view this company’s complete Cap Table, request access »

Acclarent Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Delphi Ventures Venture Capital Minority 000 0000 000000 0
ExploraMed Accelerator/Incubator 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Meritech Capital Partners Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Acclarent Executive Team (9)

Name Title Board
Seat
Contact
Info
Su Chong Vice President, Clinical & Regulatory
James Zuegel Vice President, Operations
John Chang Vice President, Research & Development
Robert Wood Jr. Vice President, Strategic Planning

5 Former Executives

You’re viewing 4 of 9 executives. Get the full list »